<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572909</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRI-201</org_study_id>
    <nct_id>NCT01572909</nct_id>
  </id_info>
  <brief_title>Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous MTP-131 on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention and Stenting for ST-segment Elevation Myocardial Infarction Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized,
      double-blind, placebo-controlled study designed to assess the safety, tolerability, and
      efficacy of IV administered elamipretide (also known as MTP-131, or Bendavia) on a background
      of standard-of-care therapy for reduction of reperfusion injury in patients with first time
      acute, anterior wall ST-segment elevation myocardial infarction (STEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized,
      double-blind, placebo-controlled study designed to assess the safety, tolerability, and
      efficacy of IV administered elamipretide on a background of standard-of-care therapy for
      reduction of reperfusion injury in patients with first time acute, anterior wall STEMI.

      Patients were randomized to receive either an infusion of elamipretide at 0.05 mg/kg/hr or an
      identically appearing placebo administered as an IV infusion at 60 mL/hr. The infusion began
      at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and
      continued through approximately 1 hour following re-establishment of blood flow through the
      culprit vessel.

      The reduction of reperfusion injury, or infarct size, was estimated using the area under the
      curve (AUC) of the serum creatine kinase (CK) isoenzyme, as well as using magnetic resonance
      imaging (MRI) performed on the Day 4±1 and on Day 30±7 (both MRI assessments measured infarct
      size and the ratio of infarct size to myocardial mass). The analyses of cardiac MRI data were
      performed for both the primary endpoint population and also in all patients who had adequate
      Day 4/Day 30 cardiac MRI studies.

      After completion of the percutaneous coronary intervention (PCI) and stenting, patients
      received standard medical treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)</measure>
    <time_frame>The initial 24 and 72 hours post-percutaneous coronary intervention (PCI)</time_frame>
    <description>Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of Troponin 1 Enzyme</measure>
    <time_frame>Initial 24 and 72 hours post-PCI</time_frame>
    <description>Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass</measure>
    <time_frame>Day 30 + 7</time_frame>
    <description>Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI</measure>
    <time_frame>Initiation to Completion of PCI, no longer than 4 hours</time_frame>
    <description>TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TIMI Frame Count</measure>
    <time_frame>Completion of PCI, no longer than 4 hours</time_frame>
    <description>Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution</measure>
    <time_frame>pre-PCI to 24 hours post-PCI</time_frame>
    <description>ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine From Baseline</measure>
    <time_frame>Day 30 +7</time_frame>
    <description>Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline</measure>
    <time_frame>Day 30 +/- 7</time_frame>
    <description>Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C Change From Baseline</measure>
    <time_frame>Day 30 + 7</time_frame>
    <description>Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen (BUN) Change From Baseline</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI</measure>
    <time_frame>Baseline to 48 hours post PCI or MRI</time_frame>
    <description>Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation</measure>
    <time_frame>Baseline up to 1 hour post-PCI</time_frame>
    <description>Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Myocardial Complications: Mechanical Complications</measure>
    <time_frame>Baseline up to 1 hour post-PCI</time_frame>
    <description>Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Use of Medications During PCI Procedure</measure>
    <time_frame>Initiation to Completion of PCI, no longer than 4 hours</time_frame>
    <description>Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) Ejection Fraction (%)</measure>
    <time_frame>Day 4 to Day 30</time_frame>
    <description>Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Left Ventricular End Diastolic Volume, Corrected</measure>
    <time_frame>Day 4 and Day 30</time_frame>
    <description>Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Left Ventricular End Systolic Volume, Corrected</measure>
    <time_frame>Day 4 and Day 30</time_frame>
    <description>Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Heart Failure</measure>
    <time_frame>Within 24 hours after PCI</time_frame>
    <description>Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Reperfusion Injury</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Bendavia™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendavia (MTP-131)</intervention_name>
    <description>0.05 mg/kg/hr</description>
    <arm_group_label>Bendavia™</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Elamipretide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically appearing placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 and &lt;85 years

          -  The patient presents with first-time acute, anterior wall STEMI scheduled to undergo
             primary PCI and stenting.

          -  The patient has symptoms of cardiac ischemia of ≥10 minutes.

          -  The patient must demonstrate an anterior wall STEMI with &gt;0.1 millivolt (mV)
             ST-segment elevation in at least two contiguous precordial leads (i.e., V1-V4) or
             presumed new left bundle branch block.

          -  The time from onset of symptoms of cardiac ischemia to the anticipated time of initial
             PCI balloon inflation does not exceed four (4) hours and it is anticipated that the
             door-to-balloon time will be &lt;2 hours.

          -  For female patients of child-bearing potential, an adequate form of contraception must
             be adhered to prior to entry into the study and for a further 3 months after the
             follow-up visit. Female patients of childbearing potential must have a negative serum
             pregnancy test prior to entry into the study.

          -  Female patients not of childbearing potential (i.e. female patients who are
             postmenopausal since last regular menses, or have been surgically sterilized at least
             1 year prior to screening visit) are eligible to enter the study.

          -  For male patients with female partners of child-bearing potential, an adequate form of
             contraception must be adhered to prior to entry into the study and for a further 3
             months after the post-study medical.

          -  Written informed consent obtained that strictly adheres to the written guidelines from
             the local Institutional Review Board (IRB)/ Ethical Committee (EC).

        Exclusion Criteria

          -  Cardiogenic shock or maximal systolic blood pressure (BP) &lt;80 mm Hg after fluid and/or
             vasopressor resuscitation on at least two consecutive readings.

          -  Ongoing vasopressor support.

          -  Uncontrolled hypertension defined as a systolic BP &gt;180 mm Hg or a diastolic BP &gt;110
             mm Hg on at least two consecutive readings.

          -  Cardiac arrest or arrhythmia requiring prolonged (&gt;5 minutes) chest compressions/
             cardiopulmonary resuscitation (CPR).

          -  Prior coronary artery bypass graft surgery (CABG).

          -  Prior myocardial infarction (MI).

          -  Implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) unless known
             to be MRI safe. The presence of an MRI-compatible pacemaker or other MRI-compatible
             hardware will not be a contraindication to participation in this trial.

          -  Known left ventricular ejection fraction &lt;30% prior to the qualifying infarct.

          -  History of clinically significant hepatic disturbance or chronic renal impairment at
             the time of admission.

          -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the last 30
             days.

          -  Any known disorder that is associated with immunologic dysfunction (e.g., cancer,
             lymphoma, a positive serologic test for the human immunodeficiency virus, or
             hepatitis) more recently than 6 months before presentation or the administration of
             immunosuppressive drugs within 10 days of the STEMI at doses expected to be associated
             with immunosuppression including high dose steroids (&gt;2.5 mg/d hydrocortisone or equal
             potency of synthetic steroids), tumor necrosis factor-alpha (TNF-α) blockers or
             methotrexate/azathioprine.

          -  Any condition that, in the Investigator's opinion, would prevent adherence to the
             requirements of the protocol including language barrier or current alcohol or drug
             abuse.

          -  Contraindications (including claustrophobia) to cardiac MRI at study entry.

          -  Participation in an investigational drug or device study within the 30 days prior to
             enrollment into the EMBRACE-STEMI Trial or anticipated within the next 4 days.

          -  Female patients who are pregnant or breastfeeding during the study or intend to within
             30 days of receiving study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjan Chakrabarti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baker 4, Boston, MA 02215</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. M. Gibson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baer 4, Boston, MA 02215</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Cardiac Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin, Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhaus Klinikum Eifel</name>
      <address>
        <city>Bitburg</city>
        <zip>54634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Kardiologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal, Herzzentrum Elberfeld</name>
      <address>
        <city>Wuppertal</city>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Kardiológiai Központ, Városmajor u. 68</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honvédkórház-Állami Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE Klinikai Központ Szívgyógyászati Klinika</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent György Kórház, II. Belgyógyászati Osztály</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>H-8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Kórház, Kardiológiai Osztály, Zrínyi Miklós út 1.</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK Nr 7 Klaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, III Oddzial Kardiologii, Zklad Kardiologii Inwazjnejul, Ziolowa 45-47</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK Nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszaka Gieca, I Oddzial Kardiologii, ul. Ziolowa 45-47</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony w Kielcach, Swietokrzyskie Centrum Kardiologii</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pwla II, Centrum Interwencyjnego Leczenia Chorob Serca i Naczyn z Pododdzialem Kariologii Interwencyjnej</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im WI. Bieganskiego, II Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Lodzi, Pracownia Kardiologii Inwazyinej, ul. Kniaziewicza 1/5</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wojewodzkie Centrum Medyczne, Zaklad Diagnostyki Obrazowej, AI. W. Witosa 26</name>
      <address>
        <city>Opole</city>
        <zip>45-418</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Bielanski im. ks. Jerzego Popieluszki</name>
      <address>
        <city>Warsaw</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Pracownia Kardiologii Inwazyjnej</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnoslaski Szpital Specjalistyczny im. T. Marciniaka, Centrum Medycyny Ratunkowe</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-420</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny, ul. H. Kamieskiego 73a</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II w Zamosciu, Oddzial Kardiologii z Pododdzialem Intensywnej Terapil Kardiologicznej, ul. Aleje Jana Pawta II 10</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <results_first_submitted>April 17, 2020</results_first_submitted>
  <results_first_submitted_qc>May 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <disposition_first_submitted>November 11, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2015</disposition_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Reperfusion</keyword>
  <keyword>Primary PCI</keyword>
  <keyword>Stenting for ST-segment Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendavia™</title>
          <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Infarct, comorbidity, Pt refusal of exam</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>300 patients were randomized and only 297 were included in the Safety Population, which consists of all patients who took any fraction of study drug using actual treatment received. If patient was randomized to placebo and received elamipretide, patient’s actual treatment was recognized as elamipretide (and vice versa).</population>
      <group_list>
        <group group_id="B1">
          <title>Bendavia™</title>
          <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="297"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="11"/>
                    <measurement group_id="B2" value="60.1" spread="10.6"/>
                    <measurement group_id="B3" value="60.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)</title>
        <description>Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI</description>
        <time_frame>The initial 24 and 72 hours post-percutaneous coronary intervention (PCI)</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom CK-MB over the initial 72 hours post-PCI was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)</title>
          <description>Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom CK-MB over the initial 72 hours post-PCI was measured.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6582.0" spread="3270.6"/>
                    <measurement group_id="O2" value="6738.3" spread="3775.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5252.2" spread="2667.9"/>
                    <measurement group_id="O2" value="5471.9" spread="3270.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Troponin 1 Enzyme</title>
        <description>Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI</description>
        <time_frame>Initial 24 and 72 hours post-PCI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Troponin 1 Enzyme over the initial 72 hours post-PCI was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Troponin 1 Enzyme</title>
          <description>Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Troponin 1 Enzyme over the initial 72 hours post-PCI was measured.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5422.9" spread="3430.9"/>
                    <measurement group_id="O2" value="4647.2" spread="2834.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3301.4" spread="2192.9"/>
                    <measurement group_id="O2" value="2850.4" spread="1640.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass</title>
        <description>Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.</description>
        <time_frame>Day 30 + 7</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom ratio of volume of infarcted myocardium and left ventricular mass was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass</title>
          <description>Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom ratio of volume of infarcted myocardium and left ventricular mass was measured.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.3" spread="87.3"/>
                    <measurement group_id="O2" value="225.2" spread="90.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI</title>
        <description>TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.</description>
        <time_frame>Initiation to Completion of PCI, no longer than 4 hours</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI</title>
          <description>TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flow Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Grade 1 or 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Grade 2 or 2.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected TIMI Frame Count</title>
        <description>Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.</description>
        <time_frame>Completion of PCI, no longer than 4 hours</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom corrected TIMI perfusion grade at completion of PCI was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected TIMI Frame Count</title>
          <description>Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom corrected TIMI perfusion grade at completion of PCI was measured.</population>
          <units>corrected frame count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" spread="122.8"/>
                    <measurement group_id="O2" value="166.0" spread="286.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution</title>
        <description>ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG</description>
        <time_frame>pre-PCI to 24 hours post-PCI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom the amount of ST-segment elevation resolution from the pre-PCI electrocardiogram to the 24-hour post-PCI ECG was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution</title>
          <description>ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom the amount of ST-segment elevation resolution from the pre-PCI electrocardiogram to the 24-hour post-PCI ECG was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete (&gt;=70% resolution)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial (&lt;70% resolution)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None (&lt;30% resolution)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine From Baseline</title>
        <description>Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
        <time_frame>Day 30 +7</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Serum Creatinine was recorded at baseline and Day 30 +7.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine From Baseline</title>
          <description>Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Serum Creatinine was recorded at baseline and Day 30 +7.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="17.642"/>
                    <measurement group_id="O2" value="88.04" spread="22.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline</title>
        <description>Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
        <time_frame>Day 30 +/- 7</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Change in eGFR, from baseline to Day 30 +7 was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline</title>
          <description>Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Change in eGFR, from baseline to Day 30 +7 was measured.</population>
          <units>mL/min/SSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.33" spread="18.873"/>
                    <measurement group_id="O2" value="-8.94" spread="14.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cystatin C Change From Baseline</title>
        <description>Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
        <time_frame>Day 30 + 7</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Cystatin C was measured at baseline and Day 30 +7</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cystatin C Change From Baseline</title>
          <description>Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Cystatin C was measured at baseline and Day 30 +7</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.341"/>
                    <measurement group_id="O2" value="0.19" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen (BUN) Change From Baseline</title>
        <description>Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI</description>
        <time_frame>Baseline to Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom BUN at baseline and Day 30 was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen (BUN) Change From Baseline</title>
          <description>Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom BUN at baseline and Day 30 was measured</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.603"/>
                    <measurement group_id="O2" value="0.13" spread="2.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI</title>
        <description>Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.</description>
        <time_frame>Baseline to 48 hours post PCI or MRI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data, was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI</title>
          <description>Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data, was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation</title>
        <description>Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention</description>
        <time_frame>Baseline up to 1 hour post-PCI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Immediate Myocardial Complications--Ventricular Tachycardia or Fibrillation Requiring Medical Intervention--was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation</title>
          <description>Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Immediate Myocardial Complications--Ventricular Tachycardia or Fibrillation Requiring Medical Intervention--was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immediate Myocardial Complications: Mechanical Complications</title>
        <description>Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)</description>
        <time_frame>Baseline up to 1 hour post-PCI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom immediate Myocardial Complications (Mechanical Complications: Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation) was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Bendavia (MTP-131): 0.05 mg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identically appearing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Myocardial Complications: Mechanical Complications</title>
          <description>Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom immediate Myocardial Complications (Mechanical Complications: Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation) was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Use of Medications During PCI Procedure</title>
        <description>Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure</description>
        <time_frame>Initiation to Completion of PCI, no longer than 4 hours</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Emergency Use of Nitroprusside, Calcium Channel Blocker, or Adenosine Administration During the PCI Procedure) was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Use of Medications During PCI Procedure</title>
          <description>Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Emergency Use of Nitroprusside, Calcium Channel Blocker, or Adenosine Administration During the PCI Procedure) was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30</title>
        <description>NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)</description>
        <time_frame>Baseline to Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom NT-proBNP had been measured at baseline and Day 30 +7</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30</title>
          <description>NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom NT-proBNP had been measured at baseline and Day 30 +7</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1828.45" spread="3427.408"/>
                    <measurement group_id="O2" value="1582.67" spread="1502.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30</title>
        <description>High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)</description>
        <time_frame>Baseline to Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom hsCRP was measured at baseline and Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30</title>
          <description>High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom hsCRP was measured at baseline and Day 30.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="7.072"/>
                    <measurement group_id="O2" value="-0.91" spread="7.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular (LV) Ejection Fraction (%)</title>
        <description>Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30</description>
        <time_frame>Day 4 to Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom LV ejection fraction was measured at Day 4 and Day 30</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular (LV) Ejection Fraction (%)</title>
          <description>Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom LV ejection fraction was measured at Day 4 and Day 30</population>
          <units>percentage of blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.4"/>
                    <measurement group_id="O2" value="2.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Left Ventricular End Diastolic Volume, Corrected</title>
        <description>Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30</description>
        <time_frame>Day 4 and Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Left Ventricular End Diastolic Volume Corrected for Body Surface Area was measured on Day 4 and Day 30</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Left Ventricular End Diastolic Volume, Corrected</title>
          <description>Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Left Ventricular End Diastolic Volume Corrected for Body Surface Area was measured on Day 4 and Day 30</population>
          <units>mL/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="12.6"/>
                    <measurement group_id="O2" value="6.2" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Left Ventricular End Systolic Volume, Corrected</title>
        <description>Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30</description>
        <time_frame>Day 4 and Day 30</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom Left Ventricular End Systolic Volume was measured at Day 4 and Day 30</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Left Ventricular End Systolic Volume, Corrected</title>
          <description>Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom Left Ventricular End Systolic Volume was measured at Day 4 and Day 30</population>
          <units>mL/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.0"/>
                    <measurement group_id="O2" value="1.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Heart Failure</title>
        <description>Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).</description>
        <time_frame>Within 24 hours after PCI</time_frame>
        <population>All participants in the Primary Analysis Population (PAP) for whom CHF which began within 24 hours after PCI but within the duration of the index hospitalization was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia™</title>
            <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Heart Failure</title>
          <description>Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).</description>
          <population>All participants in the Primary Analysis Population (PAP) for whom CHF which began within 24 hours after PCI but within the duration of the index hospitalization was measured.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bendavia™</title>
          <description>Participants received Bendavia (MTP-131) as an IV infusion at 0.05 mg/kg/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo as an IV infusion at 60 mL/hr at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel via primary percutaneous coronary intervention and stenting.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedRA">Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>asystolia</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ischemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Intracardiac Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Thrombosis in Device</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sternum Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Vascular Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic Neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral Artery Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Intracardiac Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Glucose Tolerance Impairment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Carr, Pharm.D. Chief Clinical Development Officer</name_or_title>
      <organization>Stealth BioTherapeutics, Inc</organization>
      <phone>1-617-600-6888</phone>
      <email>jim.carr@stealthbt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

